Partner content Building capacity for new modalities: Inside Cytiva’s first end-to-end cGMP facility for mRNA manufacturing mRNA vaccines are a key focus for the biopharma industry. Despite this, there has been a lack of full-service Contract…
Partner content Biopharma revolutionaries lead the way as the pharmaceutical sector edges towards Industry 4.0
Is your single-use facility designed with the end in mind? Up-front design considerations can improve your long-term processing flexibility and ability to expand. Dan UpDyke, market development manager, Life Sciences, Rockwell Automation, and Timothy Wortley, senior product manager, Bioprocess Industrial Automation, Cytiva, formerly GE Healthcare,…
Partner content Implementing the ballroom concept for biomanufacturing: Lessons, reflections and considerations from experience